Supernus Pharmaceuticals
US-based Supernus Pharmaceuticals develops and markets proprietary drugs for central nervous system disorders.
Founded
2005US-based Supernus Pharmaceuticals develops and markets proprietary drugs for central nervous system disorders.
Founded in Rockville, United States, Supernus Pharmaceuticals is a specialty pharmaceutical company dedicated to developing and marketing proprietary drugs for the treatment of central nervous system (CNS) diseases and disorders. Their core mission is to improve the lives of patients with neurological and psychological conditions such as epilepsy, conduct disorder, Parkinson's disease, ADHD, and depression. The company boasts a robust portfolio of clinical-stage drugs and a strong focus on research and development to drive innovation in CNS therapies.
Supernus Pharmaceuticals has garnered attention for its award-winning contributions to the biopharmaceutical field. The company’s leadership includes notable figures in pharmaceutical research and development, though specific names are not provided. Key achievements include the successful commercialization of several CNS drugs and a promising pipeline of product candidates. Overall, Supernus Pharmaceuticals has made a significant impact on the treatment landscape for CNS disorders, enhancing patient outcomes through innovative therapeutic solutions.
Companies similar to Supernus Pharmaceuticals include Marinus Pharmaceuticals, Neurana Pharmaceuticals, Aptinyx and Acadia Pharmaceuticals.
Supernus Pharmaceuticals was founded in 2005.
Supernus Pharmaceuticals' headquarters is located in Rockville, MD, US.
Supernus Pharmaceuticals' most recent funding round was for $150M (USD) in February 2023.
As of Feb 14, 2023, Supernus Pharmaceuticals has raised a total of $689.5M (USD).
Supernus Pharmaceuticals has 612 employees as of Feb 6, 2024.
Aptinyx
aptinyx.com
